Omalizumab beyond asthma (2012)
Omalizumab beyond asthma
J. Sanchez a,b,c, R. Ramirez a, S. Diez a, S. Sus a, A. Echenique a, M. Olivares a,d,
R. Cardona a,d,∗
b Foundation for Development of Medical and Biological Sciences (FUNDEMEB), Cartagena, Colombia
c University of Cartagena, Institute for Immunological Research, Cartagena, Colombia
d Medical School, University of Antioquia, Medellín, Colombia.
∗ Corresponding author.
E-mail address: ricardona@une.net.co (R. Cardona).
Abstract
Introduction: Omalizumab has been demonstrated to be a successful therapy in the management
of asthma through reduction of patient’s symptoms and use of inhaled corticosteroids. The effect of omalizumab is achieved by immunoglobulin E (IgE) blockage and other secondary mechanisms resulting from this blockage. Because other diseases have an important IgE mediation in their physiopathology, the question arises as to if omalizumab would be useful in the treatment of other IgE-mediated diseases.
Objective: We present an overview of the experimental studies and clinical reports evaluating
the use of omalizumab in diseases different to asthma including atopic dermatitis, urticaria, eosinophilic gastrointestinal disorders, idiopathic anaphylaxis, latex allergy, hymenoptera venom allergy, and other IgE diseases.
Methods: We reviewed the literature using PUBMED, EMBASE, and LILACS for publications which used omalizumab in the treatment of patients with allergic diseases or any other diseases. Complete articles published in English, Spanish or Portuguese were included.
Conclusion: There is not enough evidence to support the regular use of omalizumab in IgE diseases other than asthma. However, some experimental and clinical investigations indicate that omalizumab could be a therapeutic option in several allergic diseases like atopic dermatitis, urticaria, and eosinophilic gastrointestinal disorders. More control studies are needed in each IgE disease to evaluate the efficacy and safety of omalizumab in IgE mediated diseases.
Texto completo: doi:10.1016/j.aller.2011.09.011
Lectura recomendada:
ResponderEliminarUpdate on Omalizumab for Urticaria: What’s New in the Literature from Mechanisms to Clinic
Désirée E. S. Larenas-Linnemann 1 & Claudio A. S. Parisi 2 & Carla Ritchie 3 & Ricardo Cardona-Villa 4 & Ivan Cherrez-Ojeda 5 & Annia Cherrez 6,7 & Luis Felipe Ensina 8 & Elizabeth Garcia 9 & Iris V. Medina 10 & Mónica Rodríguez-González 11 & Jorge Mario Sánchez Caraballo 4
Abstract
Purpose of Review Since omalizumab has been approved for urticaria, numerous randomized and real-life observational trials have been published. We reviewed the period January 2017–February 2018.
Recent Findings Omalizumab is effective for the control of urticaria recalcitrant to antihistamines in different populations globally. The ratio of total serum IgE 4-week/baseline ≥2 can predict response with a high likelihood. In observational real-life trials, doses have been adjusted on an individual basis: in some populations, up to two-thirds of the patients can be controlled with 150 mg/ month; however, others are still not controlled with 300 mg/month. In these, 150 mg bimonthly could be tried, before up-dosing to 450 mg/month. On the long run (up to 3 years) omalizumab kept its efficacy. In many patients, dosing intervals could be augmented (6–8 weeks, some even more). After a 12-month treatment, about 20% showed long-term remission without relapse.
Summary Some biomarkers are being detected. Adjusting omalizumab doses in urticaria patients could enhance efficacy (short- ening dosing interval and/or augmenting dose) and save costs (after 12 months: extending dosing interval and/or reducing dose).
Current Allergy and Asthma Reports (2018) 18:33
https://doi.org/10.1007/s11882-018-0787-5